JPWO2020026212A5 - - Google Patents

Claims (20)

1. A method of making personalized blood vessels, comprising contacting a surface of an acellular tubular scaffold with a suspension comprising a whole blood sample from a subject in need of said personalized blood vessels, A method wherein the whole blood sample is diluted in a physiological solution and the contacting procedure is performed for 3-14 days . 2. The method of claim 1 , wherein a population of cells within said whole blood sample colonize said acellular tubular scaffold. The whole blood sample contains one or more non-cellular factors, one or more non-vascular factors of the whole blood colonize the scaffold, and these non-vascular factors cause cellularization of the acellular tubular scaffold. and promoting host compatibility of the vessel upon transplantation . 2. The method of claim 1 , wherein the suspension comprising the whole blood sample further comprises an antithrombotic factor. 5. The method of claim 4 , wherein said antithrombotic factor comprises an anticoagulant. 6. The method of claim 5 , wherein said anticoagulant comprises heparin or dextran. 6. The heparin is present in a suspension containing the whole blood sample at a concentration of about 0.5 IU/ml to about 150 IU/ml when the contacting operation of the acellular tubular scaffold is initiated. The method described in . 8. The method of claim 7 , wherein the heparin is present in a suspension containing the whole blood sample at a concentration of about 6.7 IU/ml when the contacting operation of the acellular tubular scaffold is initiated. 7. The method of claim 6 , wherein said dextran is dextran-40. 6. The dextran is present in a suspension containing the whole blood sample at a concentration of about 1 g/L to about 55 g/L when the contacting operation of the acellular tubular scaffold is initiated. The method described in . 5. The method of claim 4 , wherein said antithrombotic agent comprises ascorbic acid. Claim 11 , wherein the ascorbic acid is present in a suspension containing the whole blood sample at a concentration of about 0.2 µg/ml to about 200 µg/ml when the contacting operation of the acellular tubular scaffold is initiated. The method described in . 12. The method of claim 11 , wherein the ascorbic acid is present in a suspension containing the whole blood sample at a concentration of about 5 [mu]g/ml when the acellular tubular scaffold contacting operation is initiated. 5. The method of claim 4 , wherein said antithrombotic agent comprises acetylsalicylic acid. 15. The acetylsalicylic acid is present in a suspension containing the whole blood sample at a concentration of about 0.2 μg/ml to about 200 μg/ml when the contacting operation of the acellular tubular scaffold is initiated. The method described in . 15. The method of claim 14 , wherein the acetylsalicylic acid is present in a suspension containing the whole blood sample at a concentration of about 5 [mu]g/ml when initiating the contacting operation of the acellular tubular scaffold. The suspension comprising said whole blood sample further comprises a growth factor at a level equal to or greater than the population mean physiological level, the choice of growth factor being granulocyte-macrophage-colony stimulating factor (GM-CSF). , interleukin (IL)-3, IL-4, neurotrophin (NT)-6, pleiotrophin (HB-GAM), midkine (MK), interferon-inducible protein-10 (IP-10), platelet factor ( PF)-4, monocyte chemoattractant protein-1 (MCP-1), RANTES (CCL-5, chemokine (CC motif) ligand 5), IL-8, IGF, fibroblast growth factor (FGF)-l , FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, transforming growth factor (TGF)-β, VEGF, platelet-derived growth factor ( PDGF)-A, PDGF-B, HB-EGF, hepatocyte growth factor (HGF), tumor necrosis factor (TNF)-alpha, insulin-like growth factor (IGF)-1 and any combination thereof; The method of Claim 1 . 18. The method of claim 17 , wherein said growth factor is fibroblast growth factor (FGF)-2. 2. The method of claim 1, wherein said contacting operation is carried out for 3-9 days. 20. The method of claim 19, wherein said contacting operation is carried out for 4-9 days.